EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda

Martin Kamilo Angwe iD, Norah Mwebaza, Sam Lubwama Nsobya, Patrick Vudriko, Saviour Dralabu, Denis Omali, Maria Agnes Tumwebaze, Moses Ocan

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0305064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Martin Kamilo Angwe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, College of Health Science, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Plasmodium falciparum, Artemether, Lumefantrine Drug Combination, Malaria, Falciparum, Mutation. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, European and Developing Countries Clinical Trials Partnership, Foundation for the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Artemisinin resistance threatens malaria control and elimination efforts globally. Recent studies have reported the emergence of Plasmodium falciparum parasites tolerant to artemisinin agents in sub-Saharan Africa, including Uganda. The current study assessed the day 3 parasite clearance and its correlation with P . falciparum K13 propeller gene ( pfkelch13 ) mutations in P . falciparum parasites isolated from patients with uncomplicated malaria under artemether-lumefantrine (AL) treatment. This study enrolled 100 P . falciparum- positive patients to whom AL was prescribed between 09/September/2022 and 06/November/2022. Blood samples were collected in EDTA tubes before treatment initiation (day 0) and on day 3. Parasitemia was assessed by microscopy from blood smears and quantitative polymerase chain reaction (qPCR) from the DNA extracted. The day 0 parasite K13 gene was sequenced using Sanger sequencing. Sequence data were analysed using MEGA version 11 software. The data were analysed using STATA version 15, and the Mann‒Whitney U test was used to compare PCR parasite clearance on day 3 using the comparative CT value method and pfkelch13 mutations. The prevalence of day 3 parasitaemia was 24% (24/100) by microscopy and 63% (63/100) by qPCR from the AL-treated patients. P . falciparum K13 -propeller gene polymorphism was detected in 18.8% (15/80) of the day 0 DNA samples. The K13 mutations found were C469Y, 12.5% (10/80); A675V, 2.5% (2/80); A569S, 1.25%, (1/80), A578S, 1.25%, (1/80) and; F491S, 1.25%, (1/80) a new allele not reported anywhere. The C469Y mutation, compared to the wild-type, was associated with delayed parasite clearance p = 0.0278, Hodges-Lehmann estimation 3.2108 on the log scale, (95%CI 1.7076, 4.4730). There was a high prevalence of day 3 P . falciparum among malaria patients treated using artemether-lumefantrine. We conclude the presence of the K13 mutation associated with artemisinin resistance by P . falciparum in Adjumani district, Uganda, necessitates regular surveillance of the effectiveness and efficacy of artemether-lumefantrine in the country.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumArtemether, Lumefantrine Drug CombinationMalaria, FalciparumMutationAntimalarialsParasitemiaHumansUgandaMaleFemaleProtozoan ProteinsAdultChildAdolescentChild, PreschoolYoung AdultDrug ResistanceArtemisininsMiddle Aged

Substanzen

Artemether, Lumefantrine Drug CombinationAntimalarialsProtozoan ProteinsArtemisinins

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, College of Health Science, Makerere University, Kampala, Uganda.
  • Research Center for Tropical Diseases and Vector Control, Department of Pharmacy, Clinical and Comparative Medicine, School of Veterinary Medicine and Animal Resources, College of Veterinary Medicine, Animal Resources a…
  • Department of Biomolecular Resources and Biolab Sciences, School of Biosecurity, Biotechnical and Laboratory Science, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Ugand…
  • Infectious Diseases Research Collaboration, Makerere University, Kampala, Uganda.
  • Infectious Disease Institute, Makerere University, Kampala, Uganda.

ORCID-Profile: Martin Kamilo Angwe

Förderung

  • FIC NIH HHS
  • European and Developing Countries Clinical Trials Partnership
  • Foundation for the National Institutes of Health

Zitieren

APA

Angwe, M. K., Mwebaza, N., Nsobya, S. L., Vudriko, P., Dralabu, S., Omali, D., Tumwebaze, M. A., & Ocan, M. (2024). Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda. PLOS ONE. https://doi.org/10.1371/journal.pone.0305064

Vancouver

Angwe MK, Mwebaza N, Nsobya SL, Vudriko P, Dralabu S, Omali D, et al. Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda. PLOS ONE. 2024. doi:10.1371/journal.pone.0305064

BibTeX
@article{Angwe2024,
  author = {Angwe, Martin Kamilo and Mwebaza, Norah and Nsobya, Sam Lubwama and Vudriko, Patrick and Dralabu, Saviour and Omali, Denis and Tumwebaze, Maria Agnes and Ocan, Moses},
  title = {Day 3 parasitemia and Plasmodium falciparum Kelch 13 mutations among uncomplicated malaria patients treated with artemether-lumefantrine in Adjumani district, Uganda},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0305064}
}
Kostenlos starten →